Status:
COMPLETED
Feasibility of a Cytokine Expression Profile in Immune Cells as an Orientation Tool in Therapeutic Decisions for Auto-inflammatory and Auto-immune Diseases
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study will assess the feasibility of using cytokine expression profiles in blood samples as a method for evaluating rheumatoid polyarthritis
Eligibility Criteria
Inclusion
- The patient must have given their free and informed consent and signed the consent form
- The patient must be a member or beneficiary of a health insurance plan
- Patient is at least 18 years old
- Subjects included as patients have rheumatoid polyarthritis according to ACR EULA 2010, DAS28\>3.2 criteria
- Subjects included as controls are healthy volunteers who have no overexpression of cytokines
Exclusion
- The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study
- The subject refuses to sign the consent
- It is impossible to give the subject informed information
- The patient has had at least 3 months of specific treatment that can potentially impact cytokine profile
Key Trial Info
Start Date :
November 24 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 12 2022
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT03280797
Start Date
November 24 2017
End Date
January 12 2022
Last Update
January 25 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Montpellier
Montpellier, France, 34295
2
CHU Nimes
Nîmes, France, 30029